QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
Log in
OTCMKTS:RSLSD

ReShape Lifesciences Stock Forecast, Price & News

$5.37
+0.12 (+2.29 %)
(As of 12/9/2019)
Add
Compare
Today's Range
$4.55
Now: $5.37
$5.37
50-Day Range
$5.37
MA: $5.50
$5.55
52-Week Range
$2.91
Now: $5.37
$82.80
Volume6,500 shs
Average Volume1,362 shs
Market Capitalization$1.90 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03
ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.51 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RSLSD
CUSIPN/A
CIKN/A
Phone949-429-6680
Employees43

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$610,000.00
Cash Flow$67.13 per share
Book Value$341.84 per share

Profitability

Net Income$-81,150,000.00
Net Margins-668.58%

Miscellaneous

Market Cap$1.90 million
Next Earnings DateN/A
OptionableNot Optionable
$5.37
+0.12 (+2.29 %)
(As of 12/9/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive RSLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for RSLSD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ReShape Lifesciences (OTCMKTS:RSLSD) Frequently Asked Questions

How has ReShape Lifesciences' stock price been impacted by COVID-19?

ReShape Lifesciences' stock was trading at $5.45 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RSLSD shares have decreased by 1.5% and is now trading at $5.37.
View which stocks have been most impacted by COVID-19
.

Who are some of ReShape Lifesciences' key competitors?

Who are ReShape Lifesciences' key executives?

ReShape Lifesciences' management team includes the following people:
  • Mr. Barton P. Bandy, Pres, CEO & Director (Age 58)
  • Dr. Mark B. Knudson, Co-Founder and Special Advisor to the CEO (Age 70)
  • Dr. Katherine S. Tweden Ph.D., Co-Founder (Age 58)
  • Mr. Thomas Stankovich, Chief Financial Officer (Age 58)
  • Mr. Vipul Shah, Sr. VP of Operations and R&D

What is ReShape Lifesciences' stock symbol?

ReShape Lifesciences trades on the OTCMKTS under the ticker symbol "RSLSD."

How do I buy shares of ReShape Lifesciences?

Shares of RSLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ReShape Lifesciences' stock price today?

One share of RSLSD stock can currently be purchased for approximately $5.37.

How big of a company is ReShape Lifesciences?

ReShape Lifesciences has a market capitalization of $1.90 million and generates $610,000.00 in revenue each year. ReShape Lifesciences employs 43 workers across the globe.

What is ReShape Lifesciences' official website?

The official website for ReShape Lifesciences is www.reshapelifesciences.com.

How can I contact ReShape Lifesciences?

ReShape Lifesciences' mailing address is 1001 Calle Amanecer, Clemente CA, 92673. The company can be reached via phone at 949-429-6680 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.